fexinidazole will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. trastuzumab, brentuximab vedotin. Comment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. If you miss a dose, ask your doctor or pharmacist right away for a new dosing schedule. doi: 10.1200/JCO.2011.38.0410. Newland A. M., Li J. X., Wasco L. E., Aziz M. T., Lowe D. K. Brentuximab vedotin: a CD30-Directed antibody-cytotoxic drug conjugate. 2021 Aug;8(8):e562-e571. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates. trailer
Monitor Closely (1)tazemetostat will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor patients for adverse reactions. Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas [abstract]. Modify Therapy/Monitor Closely. Conflict-of-interest disclosure: R.T.M. Fifteen minutes later, the symptoms of chest pain and shortness of breath persisted, so hydrocortisone at 100 mg IV was administered, with an additional 25 mg of IV diphenhydramine and 20 mg of IV famotidine. Use Caution/Monitor. The first dose of brentuximab vedotin was administered without difficulty, at full dose (1.8 mg/kg) at a standard infusion time of 30 minutes. . Use Caution/Monitor. Federal government websites often end in .gov or .mil. and formulary information changes. trastuzumab deruxtecan, brentuximab vedotin. sotorasib will decrease the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. abametapir will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases toxicity of the other by immunosuppressive effects; risk of infection. A patient receiving an initial brentuximab infusion experiences severe respiratory distress requiring inthubation. <]>>
A simplified grading scale derived from the CTCAE was also created. Use Caution/Monitor. Monitor patients for adverse reactions. By clicking send, you acknowledge that you have permission to email the recipient with this information. levoketoconazole increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Editorial assistance was provided by Marie Louise Edwards, Lei Yin, and Yichen Lu from Analysis Group, Inc., and was supported by Novartis Pharmaceuticals Corporation. Use Caution/Monitor. Monitor Closely (1)imatinib increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Brentuximab vedotin is also used in adults whose cancer has not gotten better after at least two treatments with combination chemotherapy and who cannot receive an ASCT. Patients were randomly assigned in a 1:1 ratio to receive A+AVD (1.2 mg of brentuximab vedotin per kilogram of body weight, 25 mg of doxorubicin per square meter of body-surface area . Cancer Chemother Pharmacol. Avoid or Use Alternate Drug. . Avoid or Use Alternate Drug. She was treated with six cycles of chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), to which she obtained a complete response by positron emission tomography-computed tomography (PET-CT) criteria. Reevaluation according to the mCRES/ASTCT criteria downgraded 31 events deemed NT by CTCAE to grade 0. Use Caution/Monitor. z $3-^DpR-!Fi&\Arb,kYRZglm`. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Limitations of this analysis include its retrospective nature and the consequent insufficient detail for full implementation of the CARTOX grading system (eg, the prospective part of the CARTOX-10 score questionnaire), thus requiring the grouping of grade 1/2 NT events together. It is possible that a similar process would also lead to decreased numbers of NT events attributable to CAR-T cell therapy for ZUMA-1 and TRANSCEND. To view formulary information first create a list of plans. doi: 10.1007/s00280-002-0447-1. !2$0f . Thus, the CTCAE scale identified 31 more patients as having NT than did either the mCRES system or the ASTCT system. Hematology-Oncology Guidelines: 2017 Midyear Review. Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities.Serious - Use Alternative (1)tucatinib will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. A toxicity grading scale is provided for each AE term, it varies from 1 (mild) to 5 (death). Acute pulmonary toxicity associated with brentuximab appears to be a rare but serious adverse effect that can be potentially fatal. . Use Caution/Monitor. It is given as directed by your doctor, usually once every 2 or 3 weeks.The dosage is based on your medical condition, weight, and response to treatment.Your health care professional will monitor you during the infusion in case you develop a reaction to brentuximab. Use Caution/Monitor. %%EOF
Monitor patients for adverse reactions. National Cancer Institute (A) Classification of NT by CTCAE, mCRES, and ASTCT grading systems (N = 111). 0000010614 00000 n
}? Journal of the National Comprehensive Cancer Network : JNCCN. Using a diffuse and overlapping variety of CTCAE NT terms can create confusion, misreporting, and suboptimal clinical management of NT associated with CAR-T cell therapy. Minor/Significance Unknown. Monitor Closely (1)phenytoin decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)indinavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Federal government websites often end in .gov or .mil. doi: 10.1016/S2352-3026(18)30153-4. Use Caution/Monitor. If you develop a less serious infusion reaction, you will be directed by your doctor to take certain medications (such as acetaminophen, antihistamines, corticosteroids) before each future brentuximab infusion to lessen the chance of symptoms. Use Caution/Monitor. carbamazepine decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Comment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. hb```b``,G@Y8&8Jp6qsE30y?avw
b9WGK`h!l10Yl3LWFMff:d`R( |> b`R`q@J@ 5!
. and a collection of links to more information about the use of NCI CTCAE v5.0 hematologic toxicity Neutropenia, thrombocytopenia, anemia, and lymphocytopenia are determined from the complete blood count. endobj
113 0 obj <>
endobj
Serious - Use Alternative (1)lasmiditan increases levels of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. Monitor Closely (1)berotralstat will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, Pillon M, Aladjidi N, Klingebiel T, Landman-Parker J, Medina-Sanson A, August K, Sachs J, Hoffman K, Kinley J, Song S, Song G, Zhang S, Suri A, Gore L. Lancet Haematol. cenobamate will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)fexinidazole will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. Use Caution/Monitor. These 31 patients generally presented with either nervous system disorders such as syncope, dizziness, peripheral neuropathy, and hypotonia that seemed distinct from and did not raise clinical suspicion of encephalopathy, or psychiatric disorders such as anxiety and insomnia (Table 2). If not feasible, avoid use of abametapir. ofatumumab SC, brentuximab vedotin. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: bleomycin, other drugs that weaken the immune system/increase the risk of infection (such as natalizumab, rituximab). is employed by the Analysis Group, which received research funding from Novartis. Correspondence: Richard T. Maziarz, Adult Blood and Marrow Stem Cell Transplant & Cellular Therapy Program, Knight Cancer Institute, Oregon Health and Science University, Mail code: OC14HO, 3181 SW Sam Jackson Park Rd, Portland, OR 97239; e-mail: [email protected]. . 2005;66(1):p. 195. doi: 10.1016/j.urology.2005.01.038. Stay away from anyone who has an infection that may easily spread (such as chickenpox, COVID-19, measles, flu). };wN:iyUFYg,Wyi^dgvBMu9L> {Ij{>i JS8Lk6P&adAQWEPN_aKe7+S|O[u/_>v~?W I}yr>T%D$D5fqYsms
xp
`sv@K4([MhT3O - Febrile neutropenia - - ANC <1000/mm3 with a single temperature of >38.3 degrees C (101 degrees F) or a sustained temperature of >=38 degrees C (100.4 degrees F) for more than one hour Life-threatening consequences; urgent intervention indicated Death Definition: Typically, CTCAE grading is directly collected from the site on the adverse experience case report form. tazemetostat will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. We compare the results of regrading by CTCAE to the original FDA data report, as well as regrading by CTCAE compared with a modified CRES (mCRES) score and the ASTCT ICANS score. Modify Therapy/Monitor Closely. Modify Therapy/Monitor Closely. Minor/Significance Unknown. The data availability of these trials is according to the criteria and process described on www.clinicalstudydatarequest.com. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. . Patients with concurrent CRS also often receive anti-interleukin-6 agents.1 In severe cases, rapidly fatal cerebral edema has occurred in CAR-T cell trials (eg, the JCAR015 ROCKET [Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia] trial in adult ALL), although none was observed in the JULIET (A Phase 2, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory DLBCL) lymphoma trial.10,20-22. Grading based on National Cancer Institute (NCI)Common Terminology Criteria for Adverse Events (CTCAE . Use Caution/Monitor. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug.Tell your doctor if you are pregnant or plan to become pregnant. Copyright(c) 2023 First Databank, Inc. endstream 8600 Rockville Pike Unauthorized use of these marks is strictly prohibited. unspecified interaction mechanism. 0000004470 00000 n
Patients treated with selinexor may experience neurological toxicities. hbbd``b`"\35`= sharing sensitive information, make sure youre on a federal Avoid or Use Alternate Drug. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease, liver disease, diabetes.Brentuximab can make you more likely to get infections or may make current infections worse. Monitor Closely (1)rifabutin decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. To lower your risk, your doctor may add a medication and tell you to drink plenty of fluids. doi: 10.1016/S2352-3026(21)00170-8. Monitor Closely (1)dexamethasone decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. <>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/StructParents 0>>
If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs. commonly, these are generic drugs. endstream
endobj
1187 0 obj
<>/Metadata 39 0 R/OCProperties<>/Outlines 66 0 R/PageLabels 1182 0 R/PageLayout/OneColumn/Pages 1184 0 R/PieceInfo<>>>/StructTreeRoot 79 0 R/Type/Catalog>>
endobj
1188 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/StructParents 0/Type/Page>>
endobj
1189 0 obj
<>stream
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Monitor Closely (1)phenobarbital decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Standard epinephrine and methylprednisolone were available at the bedside in the event of any anaphylactic reaction. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. (a) Computed tomography (CT) of the chest showing patchy, nodular ground glass opacities along a bronchovascular distribution throughout both lungs. Minor/Significance Unknown. Monitor patients for adverse reactions. The most current release files are in order of appearance: CTCAE_5.0; CTCAE v5.0 in the NCI Thesaurus .xlsx format; CTCAE v5.0 in the NCI Thesaurus .xls format; CTCAE v5.0 in the original CTEP .xlsx format cyclophosphamide will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. erdafitinib will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. This drug is available at the lowest co-pay. Novartis Pharmaceuticals Corporation Web site. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer. For example, mCRES and ASTCT criteria categorized 31 patients as having grade 0 NT compared with NT ranging from grade 1 to 3, using the CTCAE scale. rucaparib will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Seattle, WA: Business Wire; July 7, 2016, Preliminary results of prophylactic tocilizumab after axicabtagene ciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL), Chimeric antigen receptor T-cell therapy - assessment and management of toxicities, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, United Kingdom National Cancer Research Institute, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. lenacapavir will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ketoconazole increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consider dose reduction of sensitive CYP3A4 substrates.istradefylline will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. lFsA Contraindicated. Monitor Closely (1)fosamprenavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. . Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. palifermin increases toxicity of brentuximab vedotin by Other (see comment). %%EOF
Use Caution/Monitor. Monitor Closely (1)brentuximab vedotin decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. nK Monitor Closely (1)trastuzumab, brentuximab vedotin. Avoid or Use Alternate Drug. 0000001178 00000 n
Monitor patients for adverse reactions. 11 0 obj With this study, we showed that the first step in investigating the complex clinical syndrome of NT associated with CAR-T cell therapies is the accurate grading, which can then be used to investigate further associations of NT and clinically relevant markers (eg, age, tumor burden).27,28. Use Caution/Monitor. Monitor patients for adverse reactions. (A) Classification of NT by CTCAE, mCRES, and ASTCT grading systems (N = 111). Monitor patients for adverse reactions. Stiripentol is a CYP3A4 inhibitor and inducer. Use Caution/Monitor. startxref
Talk to your doctor if you have been exposed to an infection or for more details.Tell your health care professional that you are using brentuximab before having any immunizations/vaccinations. S.J.S. Poster PF305, 2020 by The American Society of Hematology, Copyright 2023 by American Society of Hematology, https://doi.org/10.1182/bloodadvances.2019001305, https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf, https://www.hcp.novartis.com/products/kymriah/diffuse-large-b-cell-lymphoma-adults/safety-profile/, Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental ADL, Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL, Life-threatening consequences; urgent intervention indicated, Patient in critical condition, and/or obtunded and cannot perform assessment of tasks, Stage 1-2 papilledema, or CSF opening pressure <20 mm Hg, Stage 3-5 papilledema, or CSF opening pressure 20 mm Hg, or cerebral edema, Partial seizure, or nonconvulsive seizures on EEG with response to benzodiazepine, Generalized seizures, or convulsive or nonconvulsive status epilepticus, or new motor weakness, 0: patient is unarousable and unable to perform ICE, Patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse. The first dose of brentuximab vedotin was administered without difficulty, at full dose (1.8 mg/kg) at a standard infusion time of 30 minutes. and transmitted securely. nelfinavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Brentuximab Approved for High-Risk Hodgkin Lymphoma in Children and Adolescents, Brentuximab May Mean Less Radiation for Children, Teens with Hodgkin Lymphoma. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Use Caution/Monitor. tipranavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. belzutifan will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)lopinavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. Monitor for toxicities of P-gp substrates that may require dosage reduction when coadministered with P-gp inhibitors. CTC Version 2.0 Publish Date: April 30, 1999 Cancer Therapy Evaluation Program 1 Revised March 23, 1998 Common Toxicity Criteria, Version 2.0 DCTD, NCI, NIH, DHHS March 1998 In the majority of patients who had higher-grade NT per the CTCAE scale than the mCRES and ASTCT scales, the less specialized CTCAE scale identified NT not considered relevant for CRES or ICANS, resulting in grades of 0 by mCRES and ASTCT. You are being redirected to
%PDF-1.4 Epub 2015 Mar 19. Recognizing that the CAR-T-associated NT represents a unique syndrome that would benefit from a unified scale, the multiinstitution CAR-T cell-therapy-associated Toxicity (CARTOX) Working Group introduced the term CAR-T cell-Related Encephalopathy Syndrome (CRES).23 The CARTOX group created a CRES grading system that included a 10-point questionnaire (CARTOX-10), designed to capture subtle to severe cognitive and attentive dysfunction. Avoid or Use Alternate Drug. 0000003265 00000 n
also provided consultant services to and received payment from Novartis. . 2015 Mar;16(3):284-92. doi: 10.1016/S1470-2045(15)70013-6. Consult your doctor for more details. This drug is available at a higher level co-pay. DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. FOIA Clipboard, Search History, and several other advanced features are temporarily unavailable. elagolix will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. Eur J Haematol. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. 113 19
Reduce dose of vincristine {monograph link} based in prescribing information; Continue brentuximab dose; . sarecycline will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. Monitor patients for adverse reactions. Always ask your health care professional for complete information about this product and your specific health needs. Monitor Closely (1)nefazodone increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. xb```f``5x2@qu5mVux"jKD. Epub 2013 Nov 15. Indeed, the ZUMA-1 (Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma) trial and TRANSCEND (Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma) trials have not been regraded by an expert panel paying special attention to attribution and causation of NT. brentuximab vedotin decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. The https:// ensures that you are connecting to the Use Caution/Monitor. Use Caution/Monitor. idelalisib will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates. If a less serious reaction occurs, the infusion will be interrupted, you will be treated for the reaction, and the infusion will be continued. Serious - Use Alternative (1)ivosidenib will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If coadministration unavoidable, separate administration by at least 6 hr before or after administration of P-gp substrates with narrow therapeutic index. In addition to the ICE score, ICANS consensus grading also takes into account consciousness, seizures, motor findings, and cerebral edema.24 The ASTCT grading tool was created to provide a means to better assess and harmonize the classification of CAR-T cell therapy-associated NT and its treatment across diseases, regions, and CAR-T cell products. Monitor patients for adverse reactions. CTCAE was suboptimal for grading CAR-T cell therapy-associated NT; CRES and ASTCT scales offer more accurate assessments of ICANS. Key definitions of each NT grade for the 3 assessment tools are outlined in Table 1. A New First-line Regimen for Advanced Hodgkin Lymphoma? commonly, these are "non-preferred" brand drugs. primidone will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. B., Zhang X., et al. However, much of the information may also apply to unapproved uses that are being studied. Toxicity Grade Char * Variable Qualifier Records toxicity grade value using a standard toxicity scale (such as the NCI CTCAE). Event occurred at least once in a patient with severe (grade 3-4) CRS per Penn grade. The numbers inside of the columns refer to absolute number of patients. F.L.L. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. The .gov means its official. The sponsor is expected to provide the name of the scale and version used to map the terms, Use Caution/Monitor. 2018 Oct;5(10):e450-e461. 2015;385(9980):18531862. yt)\D)#1$\XH3RGafZ=d$4*=?&P=m^~:;#oBjE^03=^]\FI^5q!22K-x8IrHJNidwl",;f`,_F. Only 2 of the 31 patients who had NT per CTCAE, but grade 0 NT by mCRES and ASTCT, had received corticosteroids (Table 4). -. 0000004401 00000 n
Authors Please enable it to take advantage of the complete set of features! Monitor Closely (1)primidone will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fedratinib will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)enzalutamide will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Fexinidazole inhibits CYP3A4. Detailed patient characteristics were previously described.10 Ninety-two percent of patients received bridging therapy before tisagenlecleucel infusion.10 Sixty-four of 111 patients (57.7%) had CRS events, and 24 patients (21.6%) had grade 3/4 CRS events as defined by the Penn scale. Among the subgroup of 64 patients with CRS by the Penn scale, the CTCAE, mCRES, and ASTCT systems identified a rate of grade 3 or higher NT of 17.2%, 15.7%, and 15.7%, respectively (Table 6). Monitor Closely (2)elagolix will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. 2022 May 20;12:879391. doi: 10.3389/fonc.2022.879391. E.S.R. Use Caution/Monitor. Avoid or Use Alternate Drug. . Monitor Closely (1)ketoconazole increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. The CTCAE contain a grading scale for each adverse event term representing the severity of the event. MedlinePlus Information on Brentuximab Vedotin - A lay language summary of important information about this drug that may include the following: Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. rifampin decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. This strategy was based upon the results of the AETHERA phase III clinical trial (Moskowitz et al., 2015), showing improvement in progression-free survival with brentuximab vedotin consolidation therapy, post autologous transplant. Given the clear benefits of brentuximab consolidation in improving progression-free survival post transplant (Moskowitz et al., 2015) in high-risk Hodgkin lymphoma, it was thought the benefit of brentuximab vedotin consolidation outweighed the possible risks of subsequent infusions. Contraindicated because of increased risk of pulmonary toxicity.